Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HGSI -- Ignore unavailable to you. Want to Upgrade?

To: 249443 who wrote (50)	11/12/2001 1:54:19 PM
From: 249443	Respond to of 56

Transgene: yahoo.marketguide.com Transgene has a broad collaboration and license agreement with Human Genome Sciences Inc. (HGS) which gives the Company access to its collection of proprietary genes. This agreement, the first of its kind, reflects a cooperative arrangement between HGS and the Company under which both will work together to identify 10 genes with therapeutic potential. The Company is in the process of testing 35 genes in various animal models, focusing on cardiovascular diseases and oncology. The Company is obligated to pay to HGS royalties on revenues from sales of gene therapy products developed from their proprietary genes.